Antitumor Activity Seen With Fruquintinib Plus Serplulimab in Untreated, Advanced nccRCC The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

Researchers found a 9-month progression-free survival rate with the combination of fruquintinib and serplulimab for treatment-naive advanced non-clear cell renal cell carcinoma (nccRCC). @ascocancer.bsky.social #GU26 #GUCSM https://bit.ly/46APibz

KEYMAKER-U04: Targeted ICIs do not Improve Efficacy in Advanced Urothelial Cancer Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or metastatic carcinoma

In locally advanced/metastatic urothelial cancer, adding favezelimab or vibostolimab to first-line treatment with enfortumab vedotin and pembrolizumab is not associated with response or PFS, according to research presented at #GU26. #gucsm

Metastatic Prostate Cancer With Low-Volume Primary Tumors Has Poor Prognosis In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary tumors.

#Prostatecancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis.

https://bit.ly/49vP8nF

#pcsm #gucsm

Don’t miss out on the premier global event that has helped advance GU cancer science & transform patient care for more than 2 decades. Join us for #GU26 to be part of driving #gucsm innovations that improve patient care.

Register by Jan. 21 to save: brnw.ch/21wYTvj

5-Year RFS May Define “Cure” for Patients With Early Bladder Cancer Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure.

In considering outcomes for evaluating how “cure” is defined in early #bladdercancer researchers concluded that use of 5-year RFS may be suitable. Published in @eururoloncol.bsky.social.

https://bit.ly/3XnxA6p

#gucsm

Recurrent Non-Muscle Invasive Bladder Cancer Often Matches Primary Disease Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show direct progression to muscle-invasive or metastatic dise...

Recurrent non-muscle invasive #bladdercancer typically follows the same clinical and pathologic characteristics as the primary #tumor, even on second or third recurrences. Published in @elsevierconnect.bsky.social journal Clinical Genitourinary Cancer.

https://bit.ly/4oGEEH2

#NMIBC #gucsm

Electroacupuncture Accelerates Urinary Continence Return After Radical Prostatectomy - Oncology Nurse Advisor Electrical acupuncture stimulation therapy has been shown to work on other kinds of urinary incontinence, so investigators trialed the noninvasive method for continence recovery after radical prostatectomy.

Electroacupuncture to the Ciliao, Zhongliao, and Xialiao acupoints significantly accelerates time to urinary continence after radical prostatectomy for #prostatecancer, a new study finds.

https://bit.ly/4hI1yLF

#pcsm #gucsm

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo. Presented at #ESMO25 by Dr Thomas Powles of
@qmul.bsky.social. #blcsm #gucsm #ESMO2025

shorturl.at/J32bd

First-line treatment with disitamab vedotin plus toripalimab could be a new standard for patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma, according to Dr Jun Guo, who presented these results at #ESMO25. #gucsm #blcsm #ESMO2025

shorturl.at/gyhIS

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone, according to research presented at #ESMO25 by @sfreedlandmd.bsky.social of @cedarssinaicancer.bsky.social. #pcsm #gucsm #ESMO2025

shorturl.at/H6RtB

Adding perioperative enfortumab vedotin & pembrolizumab to surgical treatment can improve response and survival outcomes in patients with MIBC who are ineligible for cisplatin, according to research presented at #ESMO25. #blcsm #gucsm #esmo2025

shorturl.at/vFYcq

About Half of mCRPC Patients with BRCA1/2 Mutations Receive PARP Inhibitors Patients with mCRPC who are covered by commercial insurance are less likely to receive PARP inhibitors than those covered by government-issued insurance, researchers reported.

In the US, only around half of men with #mCRPC harboring BRCA1/2 alterations receive a PARP inhibitor. Published by @jamanetworkopen.com.

https://bit.ly/3W6WCG9

#pcsm #prostatecancer #gucsm

For pts with advanced or metastatic RCC, fruquintinib + sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus. Presented at #ESMO25 by Dr Zhenhua Liu of the West China Hospital of Sichuan University. #rccsm #gucsm #ESMO2025

shorturl.at/tzrmo

Durvalumab Plus BCG May Be New Treatment Option for BCG-Naïve, High-Risk NMIBC Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data sugg...

Adding durvalumab to induction and maintenance with BCG can improve disease-free survival in patients with BCG-naïve, high-risk NMIBC, data presented at #ESMO25 by Dr Maria De Santis of Charité Universitätsmedizin Berlin suggest. #gucsm #blcsm #ESMO2025

shorturl.at/QYecx

Time is running out to share your high-impact data at the leading global event for GU cancers, #GU26. Help drive innovation, improve patient-centered care & contribute scientific insights. Submit an abstract today! Abstracts due Oct. 21 at 11:59 PM (ET). asco.confex.com/asco/gucs202...

#gucsm

Deaths From Second Primary Malignancies Are Rising in Prostate Cancer Survivors To quantify second primary malignancy-related deaths, researchers analyzed data from the US Centers for Disease Control and Prevention's WONDER database.

The rate of death from second primary malignancies has increased among older #prostatecancer survivors in the United States.

https://bit.ly/4ocCoqB

#pcsm #gucsm

In men with prostate cancer, prophylactic whole pelvic radiotherapy does not improve OS compared to prostate-only dose-escalated radiotherapy. Presented at #ASTRO25 by Dr Mack Roach of @ucsfradonc.bsky.social.

shorturl.at/GWacU

#pcsm #gucsm #ASTRO2025

Recurrent prostate cancer patients with luminal B tumors may benefit from hormone therapy added to radiation following surgery, according to research presented at #ASTRO25.

shorturl.at/BF1EP

#pcsm #gucsm #ASTRO2025

Adjuvant radiotherapy improves locoregional failure-free survival, compared with observation, in patients with locally advanced MIBC, according to research presented at #ASTRO25. #blcsm #gucsm #astro2025
shorturl.at/kWlRH

Following ACS Survivor Guidelines Reduces Mortality in Men with Prostate Cancer Men who improve their adherence to ACS guidelines following diagnosis have a reduction in all-cause and cardiovascular mortality compared to those who maintain a low concordance with guideline recommendations.

Men with #prostatecancer who closely follow the @americancancersoc.bsky.social cancer survivor guidelines after diagnosis have lower all-cause and cardiovascular mortality compared to those who do not. Published in @jamanetworkopen.com.

https://bit.ly/4nYWww9

#pcsm #gucsm

Deaths From Second Primary Malignancies Are Rising in Prostate Cancer Survivors To quantify second primary malignancy-related deaths, researchers analyzed data from the US Centers for Disease Control and Prevention’s WONDER database.

The rate of death from second primary malignancies has increased among older prostate cancer survivors in the United States, researchers report. shorturl.at/jfuQF #pcsm #gucsm

Timing of Therapy Linked to Survival, Comorbidities Tied to Treatment Regrets, and More This article highlights recent studies that may help inform the treatment of breast, lung, prostate, and other cancers.

Recent studies have provided new insights that may help inform the treatment of breast, lung, prostate, and other cancers. Read more here: shorturl.at/arVJ2 #blcsm #bcsm #gicsm #gucsm #lcsm #pcsm

TAR-200 Improves Upon Cetrelimab in Bladder Cancer “To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in...

Adding TAR-200 to neoadjuvant treatment with cetrelimab can improve the pCR rate in patients with muscle-invasive bladder cancer set to undergo radical cystectomy, according to research published in @thelancetoncol.bsky.social. shorturl.at/RIO3F #blcsm #gucsm #mibc

BCG Intolerance Among Patients With NMIBC BCG intolerance may affect as many as 1 in 8 patients with intermediate- or high-risk NMIBC, a meta-analysis suggests.

Research suggests Bacillus Calmette-Guerin intolerance may affect as many as 1 in 8 patients with intermediate- or high-risk non-muscle invasive bladder cancer. shorturl.at/3qoD0 #blcsm #gucsm

Early On-Treatment Weight Loss Linked to Worse OS in Urothelial Carcinoma “The prognostic value of early on-treatment weight loss was independent of prognostic factors previously identified for platinum-based chemotherapy, such as age, baseline albumin, renal function, and ECOG performance status,” the researchers wrote.

Early weight loss after the start of first-line treatment with enfortumab vedotin and pembrolizumab is associated with worse OS in patients with advanced #urothelialCarcinoma.

https://bit.ly/41qZbpH

#gucsm

Sexual Health Priorities Could Guide Prostate Cancer Treatment in Gay, Bisexual Men Researchers found evidence to suggest that gay and bisexual men who prioritize insertive intercourse may experience better sexual health outcomes with external beam radiotherapy.

The preferred treatment for gay and bisexual men with prostate cancer may differ according to preferred sexual behavior, researchers report. #pcsm #gucsm

How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective Background Clinical trials are fundamental to improving cancer treatment and clinical outcomes. Whilst clinical trials offer treatment options to affected individuals, less is known about how to bes.....

Here's the link to the open access paper: onlinelibrary.wiley.com/doi/full/10....

#ClinicalTrials #GUCancer #PCSM #GUCSM

ADCs and ICIs Have Boosted Survival in Metastatic Urothelial Cancer US patients with metastatic urothelial cancer have seen improvements in survival since ICIs and ADCs have entered the market, data suggest.

According to research published in @jamanetworkopen.com, US patients with metastatic urothelial cancer have seen improvements in survival since ICIs and ADCs have entered the market. shorturl.at/DTr4z #gucsm #blcsm

Cabozantinib Plus Atezolizumab Appears More Effective Than Switching ARPIs in mCRPC “To our knowledge, CONTACT-02 is the first phase 3 study of a tyrosine kinase inhibitor-immune checkpoint inhibitor combination to show a significant improvement in progression-free survival in patien...

Findings published in @jamaoncology.com suggest that cabozantinib plus atezolizumab is more effective than switching ARPI therapy in certain #mCRPC patients. shorturl.at/j32cu #pcsm #gucsm